PMV Pharmaceuticals annual depreciation and amortization
2018
2019
2020
2021
2022
2023
2024
2025
PMV Pharmaceuticals Depreciation & Amortization Growth & History (PMVP)
PMV Pharmaceuticals's depreciation and amortization was $133,000 for fiscal 2025.
View full PMV Pharmaceuticals company overviewPMV Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $133,000 | −$1.0M | −88.37% |
| 2024 | 2024-12-31 | $1.1M | −$113,000 | −8.99% |
| 2023 | 2023-12-31 | $1.3M | $942,000 | +299.05% |
| 2022 | 2022-12-31 | $315,000 | $8,000 | +2.61% |
| 2021 | 2021-12-31 | $307,000 | −$11,000 | −3.46% |
| 2020 | 2020-12-31 | $318,000 | −$70,000 | −18.04% |
| 2019 | 2019-12-31 | $388,000 | $50,000 | +14.79% |
| 2018 | 2018-12-31 | $338,000 | — | — |
PMV Pharmaceuticals quarterly depreciation and amortization
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $24,000 | −$8,000 | −25.00% |
| Q1 2026 | 2026-03-31 | $34,000 | −$3,000 | −8.11% |
| Q4 2025 | 2025-12-31 | $33,000 | — | — |
| Q3 2025 | 2025-09-30 | $32,000 | −$339,000 | −91.37% |
| Q2 2025 | 2025-06-30 | $32,000 | −$340,000 | −91.40% |
| Q1 2025 | 2025-03-31 | $37,000 | −$325,000 | −89.78% |
| Q3 2024 | 2024-09-30 | $371,000 | $13,000 | +3.63% |
| Q2 2024 | 2024-06-30 | $372,000 | $3,000 | +0.81% |
| Q1 2024 | 2024-03-31 | $362,000 | $191,000 | +111.70% |
| Q3 2023 | 2023-09-30 | $358,000 | $284,000 | +383.78% |
| Q2 2023 | 2023-06-30 | $369,000 | $287,000 | +350.00% |
| Q1 2023 | 2023-03-31 | $171,000 | $87,000 | +103.57% |
| Q3 2022 | 2022-09-30 | $74,000 | −$6,000 | −7.50% |
| Q2 2022 | 2022-06-30 | $82,000 | $11,000 | +15.49% |
| Q1 2022 | 2022-03-31 | $84,000 | $5,000 | +6.33% |
| Q3 2021 | 2021-09-30 | $80,000 | $5,000 | +6.67% |
| Q2 2021 | 2021-06-30 | $71,000 | −$16,000 | −18.39% |
| Q1 2021 | 2021-03-31 | $79,000 | −$15,000 | −15.96% |
| Q3 2020 | 2020-09-30 | $75,000 | −$31,000 | −29.25% |
| Q2 2020 | 2020-06-30 | $87,000 | — | — |
| Q1 2020 | 2020-03-31 | $94,000 | — | — |
| Q3 2019 | 2019-09-30 | $106,000 | — | — |
PMV Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, PMV Pharmaceuticals's depreciation and amortization decreased from $318,000 to $133,000, a change of −$185,000. The latest reported quarter, Q2 2026, shows $24,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PMV Pharmaceuticals source filings ↗